These latter findings, however, were challenged by a study which correlated increased FAM57A transcript levels with unfavorable clinical parameters in prostate cancer patients and reported anti-proliferative effects of FAM57A silencing in 22Rv1 prostate cancer cells [17]. Here, TLCD3A is linked to prostate cancer.